Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech and Covance Nix Partnership

publication date: Sep 29, 2008

WuXi PharmaTech and Covance have decided not to continue their previously announced joint ownership of a preclinical laboratory, currently under construction. WuXi will now own 100% of the 323,450 square feet Suzhou facility, which was the company’s original intention. After announcing its plans to build the Suzhou facility one year ago, WuXi announced in June that it would form a 50-50 joint partnership with Covance to own and operate the facility. Now, it’s back to Plan A, which, emphasizing the positive, WuXi says will give shareholders “the full benefit” of the facility. No explanation was given for the change of plans. More details...

Stock Symbols: (NYSE: WX) (NYSE: CVD)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital